Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy

International Journal of Radiation Oncology Biology Physics

Volumn 63, Issue 1, 2005, Pages 134-140

  Cheung, Rex ^a   Kamat, Ashish M ^a   De Crevoisier, Renaud ^a   Allen, Pamela K ^a   Lee, Andrew K ^a   Tucker, Susan L ^a   Pisters, Louis ^a   Babaian, Richard J ^a   Kuban, Deborah ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Hormone; Prostate cancer; Prostatectomy; PSA failure; Radiotherapy

Indexed keywords

BIOCHEMISTRY; HORMONES; PATHOLOGY; PATIENT TREATMENT; TOXICITY;

HORMONE THERAPY; PROSTATE CANCER; PROSTATECTOMY; PSA FAILURE;

RADIOTHERAPY;

ANTIANDROGEN; GONADORELIN ANTAGONIST; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; SEMINAL VESICLE; TREATMENT FAILURE; ANALYSIS OF VARIANCE; BLOOD; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 26944440140     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.01.020     Document Type: Article

References (33)

1. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update [published erratum appears in JAMA 1997;278:118]. JAMA 1997;277:1445-1451.
2. D'Amico AVWR, Malkowicz SB, Schultz D, et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000;18:1164-1172.
3. Partin AW, Pound CR, Clemens JQ, et al. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
4. Babaian RJ, Troncoso P, Bhadkamkar VA, Johnston DA. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 2001;91:1414-1422.
5. Paulson D. Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826-1830.
6. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J Urol 1994;151:1575-1578.
7. Morris MM, Dallow KC, Zietman AL, et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997;38:731-736.
8. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996;47:232-235.
9. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 1997;24:395-406.
10. Forman JD, Meetze K, Pontes E, et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 1997;158:1436-1440.
11. Pisansky TM, Kozelsky TF, Myers RP, et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000;163:845-850.
12. Taylor N, Kelly JF, Kuban DA, et al. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 2003;56:755-763.
13. Kamat AM, Babaian K, Cheung MR, et al. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 2003;170:1860-1863.
14. Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325-1332.
15. Parker C, Warde P, Catton C. Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother Oncol 2001;61: 107-116.
16. Eulau SM, Tate DJ, Stamey TA, et al. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998;41:735-740.
17. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481.
18. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:181-220.
19. Medini E, Medini I, Reddy PK, Levitt SH. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer 1996;78:1254-1259.
20. Etzioni R, Legler JM, Feuer EJ, et al. Cancer surveillance series: Interpreting trends in prostate cancer-part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 1999;91:1033-1039.
21. Schild SE, Buskirk SJ, Wong WW, et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996; 156:1725-1729.
22. Partin AP, Landis JD, Carter PK, et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994;43:649-659.
23. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998;159:173-177; discussion 177-178.
24. Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol 2001;59: 51-60.
25. Song DY, Thompson TL, Ramakrishnan V, et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002;60:281-287.
26. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
27. Crane CH, Rich TA, Read PW, et al. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 1997;39:681-686.
28. Schild SE, Wong WW, Grado GL, et al. Radiotherapy for isolated increases in serum prostate-specific antigen levels after radical prostatectomy. Mayo Clin Proc 1994;69:613-619.
29. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 2000;48:369-375.
30. Hagan M, Zlotecki R, Medina C, et al. Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 2004;59: 329-340.
31. King CR, Presti JCJ, Gill H, et al. Radiotherapy after radical prostatectomy: Does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys 2004;59:341-347.
32. Denis LJ, Carnelo de Moura JL, Bono A, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 1993;42:119-130.
33. Basaria S, Lieb J, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779-786.